Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma.
- Author:
Katsuyuki SAKANAKA
1
;
Satoshi ITASAKA
;
Yuichi ISHIDA
;
Kota FUJII
;
Takahiro HORIMATSU
;
Takashi MIZOWAKI
;
Yoshiharu SAKAI
;
Masahiro HIRAOKA
Author Information
- Publication Type:Original Article
- Keywords: Anus neoplasms; Chemoradiotherapy; Intensity-modulated radiotherapy; Computer-assisted radiotherapy planning; Treatment outcome
- MeSH: Anus Neoplasms; Carcinoma, Squamous Cell*; Chemoradiotherapy; Epithelial Cells*; Fluorouracil; Follow-Up Studies; Genitalia; Humans; Intestines; Lymph Nodes; Mitomycin; Radiotherapy; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated*; Survival Rate; Treatment Outcome; Urinary Bladder
- From:Radiation Oncology Journal 2017;35(4):368-379
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The purpose of this study was to explore the dosimetric difference between simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) and three-dimensional conformal radiotherapy (3DCRT), and the clinical outcomes of anal squamous cell carcinoma (ASCC) chemoradiotherapy featuring SIB-IMRT. MATERIALS AND METHODS: This study included ten patients with ASCC who underwent chemoradiotherapy using SIB-IMRT with 5-fluorouracil and mitomycin C. SIB-IMRT delivered 54 Gy to each primary tumor plus metastatic lymph nodes and 45 Gy to regional lymph nodes, in 30 fractions. Four patients received additional boosts to the primary tumors and metastatic lymph nodes; the median total dose was 54 Gy (range, 54 to 60 Gy). We additionally created 3DCRT plans following the Radiation Therapy Oncology Group 9811 protocol to allow dosimetric comparisons with SIB-IMRT. Locoregional control, overall survival, and toxicity were calculated for the clinical outcome evaluation. RESULTS: Compared to 3DCRT, SIB-IMRT significantly reduced doses to the external genitalia, bladder, and intestine, delivering the doses to target and elective nodal region. At a median follow-up time of 46 months, 3-year locoregional control and overall survival rates were 88.9% and 100%, respectively. Acute toxicities were treated conservatively. All patients completed radiotherapy with brief interruptions (range, 0 to 2 days). No patient experienced ≥grade 3 late toxicity during the follow-up period. CONCLUSION: The dosimetric advantages of SIB-IMRT appeared to reduce the toxicity of chemoradiotherapy for ASCC achieving high locoregional control in the extended period.
